Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.
Identifieur interne : 001910 ( Ncbi/Merge ); précédent : 001909; suivant : 001911Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.
Auteurs : Vicky L. Marshall [Royaume-Uni] ; Jim Patterson ; Donald M. Hadley ; Katherine A. Grosset ; Donald G. GrossetSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Female, Follow-Up Studies, Humans, Iodine Radioisotopes (diagnostic use), Male, Middle Aged, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (radionuclide imaging), Retrospective Studies, Substance Withdrawal Syndrome (radionuclide imaging), Tomography, Emission-Computed, Single-Photon, Tropanes (diagnostic use).
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , diagnostic use : Iodine Radioisotopes, Tropanes.
- chemical , therapeutic use : Antiparkinson Agents.
- drug therapy : Parkinsonian Disorders.
- radionuclide imaging : Parkinsonian Disorders, Substance Withdrawal Syndrome.
- Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Tomography, Emission-Computed, Single-Photon.
Abstract
Between 4% and 14% of patients diagnosed with Parkinson's disease and entering clinical trials have normal presynaptic dopaminergic imaging. The effects of antiparkinsonian therapy have varied in these studies, and the consequences of stopping treatment are not reported. We present 11 patients who initially fulfilled diagnostic criteria and were treated for Parkinson's disease but in whom emerging diagnostic doubts led to antiparkinsonian therapy withdrawal, which was achieved without deterioration. Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials.
DOI: 10.1002/mds.21159
PubMed: 17078059
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A29
- to stream PubMed, to step Curation: 002A29
- to stream PubMed, to step Checkpoint: 002A72
Links to Exploration step
pubmed:17078059Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.</title><author><name sortKey="Marshall, Vicky L" sort="Marshall, Vicky L" uniqKey="Marshall V" first="Vicky L" last="Marshall">Vicky L. Marshall</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom. v.marshall@clinmed.gla.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author><author><name sortKey="Patterson, Jim" sort="Patterson, Jim" uniqKey="Patterson J" first="Jim" last="Patterson">Jim Patterson</name></author><author><name sortKey="Hadley, Donald M" sort="Hadley, Donald M" uniqKey="Hadley D" first="Donald M" last="Hadley">Donald M. Hadley</name></author><author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A" last="Grosset">Katherine A. Grosset</name></author><author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G" last="Grosset">Donald G. Grosset</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21159</idno><idno type="RBID">pubmed:17078059</idno><idno type="pmid">17078059</idno><idno type="wicri:Area/PubMed/Corpus">002A29</idno><idno type="wicri:Area/PubMed/Curation">002A29</idno><idno type="wicri:Area/PubMed/Checkpoint">002A72</idno><idno type="wicri:Area/Ncbi/Merge">001910</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.</title><author><name sortKey="Marshall, Vicky L" sort="Marshall, Vicky L" uniqKey="Marshall V" first="Vicky L" last="Marshall">Vicky L. Marshall</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom. v.marshall@clinmed.gla.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea><wicri:noRegion>Glasgow</wicri:noRegion></affiliation></author><author><name sortKey="Patterson, Jim" sort="Patterson, Jim" uniqKey="Patterson J" first="Jim" last="Patterson">Jim Patterson</name></author><author><name sortKey="Hadley, Donald M" sort="Hadley, Donald M" uniqKey="Hadley D" first="Donald M" last="Hadley">Donald M. Hadley</name></author><author><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A" last="Grosset">Katherine A. Grosset</name></author><author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G" last="Grosset">Donald G. Grosset</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Retrospective Studies</term><term>Substance Withdrawal Syndrome (radionuclide imaging)</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Tropanes (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Iodine Radioisotopes</term><term>Tropanes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Parkinsonian Disorders</term><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Between 4% and 14% of patients diagnosed with Parkinson's disease and entering clinical trials have normal presynaptic dopaminergic imaging. The effects of antiparkinsonian therapy have varied in these studies, and the consequences of stopping treatment are not reported. We present 11 patients who initially fulfilled diagnostic criteria and were treated for Parkinson's disease but in whom emerging diagnostic doubts led to antiparkinsonian therapy withdrawal, which was achieved without deterioration. Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17078059</PMID><DateCreated><Year>2006</Year><Month>12</Month><Day>27</Day></DateCreated><DateCompleted><Year>2007</Year><Month>02</Month><Day>20</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.</ArticleTitle><Pagination><MedlinePgn>2247-50</MedlinePgn></Pagination><Abstract><AbstractText>Between 4% and 14% of patients diagnosed with Parkinson's disease and entering clinical trials have normal presynaptic dopaminergic imaging. The effects of antiparkinsonian therapy have varied in these studies, and the consequences of stopping treatment are not reported. We present 11 patients who initially fulfilled diagnostic criteria and were treated for Parkinson's disease but in whom emerging diagnostic doubts led to antiparkinsonian therapy withdrawal, which was achieved without deterioration. Such cases represent a nondegenerative form of Parkinsonism, which does not benefit from dopaminergic therapy. Prospective vigilance regarding this category is of importance in clinical practice and clinical trials.</AbstractText><CopyrightInformation>Copyright 2006 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Vicky L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom. v.marshall@clinmed.gla.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hadley</LastName><ForeName>Donald M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Grosset</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Grosset</LastName><ForeName>Donald G</ForeName><Initials>DG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014326">Tropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>155797-99-2</RegistryNumber><NameOfSubstance UI="C087552">2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007457">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014326">Tropanes</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21159</ArticleId><ArticleId IdType="pubmed">17078059</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G" last="Grosset">Donald G. Grosset</name><name sortKey="Grosset, Katherine A" sort="Grosset, Katherine A" uniqKey="Grosset K" first="Katherine A" last="Grosset">Katherine A. Grosset</name><name sortKey="Hadley, Donald M" sort="Hadley, Donald M" uniqKey="Hadley D" first="Donald M" last="Hadley">Donald M. Hadley</name><name sortKey="Patterson, Jim" sort="Patterson, Jim" uniqKey="Patterson J" first="Jim" last="Patterson">Jim Patterson</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Marshall, Vicky L" sort="Marshall, Vicky L" uniqKey="Marshall V" first="Vicky L" last="Marshall">Vicky L. Marshall</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001910 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001910 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:17078059
|texte= Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17078059" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |